ClinicalTrials.gg
CompletedNCT02407431Updated Nov 12, 2026

PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort

An observational study in Idiopathic Pulmonary Fibrosis, sponsored by University of Pittsburgh. Completed at 5 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Pittsburgh · Observational

How we know

Updated Nov 12, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
25th of 45
200 · median 320
Started
2015
with 10 others
Observational
46 of 236
13 open now
Registered
89th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 25th largest by enrollment of the 45 observational ones that give a count, is one of 11 that started in 2015, is one of 46 observational ones, and was the 89th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.

Read the detailed description

The primary objective is to create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network. Creating the IPF Clinician-Patient Partnership Cohort will involve:

  1. Recruiting patients with IPF to participate in the PaTH Network IPF Clinician-Patient Partnership Cohort
  2. Administering surveys to the IPF Clinician-Patient Partnership Cohort approximately every 3 months to collect patient reported outcomes (PROs)
  3. Merging individual patient health record data into the IPF Clinician-Patient Partnership Cohort database
  4. Tracking whether the patient participant has biospecimens in a PaTH site biorepository and prepare for possible sharing of biospecimens in future studies.
  5. Determining if an automated procedure for identifying duplicate patients across PaTH institutions without the use of protected health information (PHI) is valid compared to a manual matching procedure using PHI.
  6. Identifying potential participants for future research studies.

The secondary objectives are to use the PaTH Network IPF Clinician-Patient Partnership Cohort to answer patient-centered research questions including:

  1. What is the prevalence of gastroesophageal reflux disease (GERD) in IPF, and what effect does GERD and its treatment have on IPF disease progression, quality of life, and survival?
  2. What is the association of oxygen use with survival, quality of life, exercise tolerance, neurocognitive function, and dyspnea?
  3. How often do IPF patients have advance directives, how often are advance directives documented in the electronic health record, and does having an advance directive influence how/where IPF patients die, their health care utilization, satisfaction with care, and quality of life?
03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target study population is adults with IPF who receive health care at one of the PaTH Network institutions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The target study population is adults identified as having IPF (through the PaTH IPF computable phenotype algorithm or a local IPF registry).

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Deceased
  • Not proficient in English
  • Has not had at least one outpatient encounter in the past 18 months at the PaTH health system's pulmonary specialty clinic through which they are recruited
  • Lung transplant
  • Already enrolled in the PaTH Clinician-Patient Partnership Cohort at another PaTH institution
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Create PaTH Network IPF Clinician-Patient Partnership Cohort

    Create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network.

    Time frame: 18 months

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Oct 2015, 4 months.

Of 74 non-industry observational studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's 4 months is below that.

Counting every sponsor, half of 88 studies reached it within 51 months; a quarter within 29 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2015 → Jun 2015, primary completion Jul 2030 → Oct 2015 and completion Jul 2030 → Oct 2017.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2015
First posted
Apr 3, 2015
StartActual
Jun 1, 2015was Mar 2015
Primary completionActual
Oct 24, 2015was Jul 2030
CompletionActual
Oct 24, 2017was Jul 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Start date
Mar 2015→Jun 1, 2015
Nov 12, 2026
Primary completion
Jul 2030→Oct 24, 2015 (actual)
Nov 12, 2026
Study completion
Jul 2030→Oct 24, 2017 (actual)
Nov 12, 2026
Enrollment
1000 (estimated)→200 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Start date Mar 2015→Jun 1, 2015
    Primary completion Jul 2030→Oct 24, 2015 (now actual)
    Study completion Jul 2030→Oct 24, 2017 (now actual)
    Enrollment 1000 (estimated)→200 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02407431
Responsible party
Kathleen McTigue (Professor, University of Pittsburgh) — Principal investigator
First posted
Apr 3, 2015
Start date
Jun 1, 2015
Primary completion
Oct 24, 2015
Completion
Oct 24, 2017
Last update
Nov 12, 2026

Study contacts

Kathleen McTigue, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion